Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC1R | Q01726 | 10/20 | 0.47 |
| ▸ | MC4R | P32245 | 10/20 | 0.47 |
| ▸ | MC5R | P33032 | 9/20 | 0.47 |
| ▸ | MC3R | P41968 | 8/20 | 0.47 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1324267 | 1.00 | MC1R (0.47) | MC1RMC4RMC5RMC3RREN | |
| SCHEMBL15673579 | 0.92 | MC4R (0.49) | MC1RMC4RMC5RMC3RPOLB | |
| SCHEMBL15673580 | 0.92 | MC4R (0.49) | MC1RMC4RMC5RMC3RPOLB | |
| SCHEMBL15673363 | 0.90 | MC1R (0.47) | MC1RMC4RMC5RMC3RREN | |
| SCHEMBL3689944 | 0.89 | MC4R (0.41) | MC1RMC4RMC5RMC3RREN | |
| SCHEMBL1308356 | 0.87 | MC1R (0.56) | MC1RMC4RMC5RMC3RREN | |
| SCHEMBL2315452 | 0.85 | MC1R (0.51) | MC1RMC4RMC5RMC3RREN | |
| SCHEMBL1324502 | 0.84 | MC4R (0.41) | MC1RMC4RMC5RMC3RHTT | |
| SCHEMBL1324438 | 0.84 | MC4R (0.41) | MC1RMC4RMC5RMC3RHTT | |
| SCHEMBL1307814 | 0.84 | MC4R (0.43) | MC1RMC4RMC5RMC3RHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | claimed |
| EP-2352729-B1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-14 | — | — | EP | claimed |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-17 | — | — | US | claimed |
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-11-19 | — | — | US | disclosed |
| US-8962846-B2 | Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-02-24 | — | — | US | disclosed |
| EP-2352729-B1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RES & DEV (FR) | 2014-05-14 | — | — | EP | disclosed |
| WO-2012131090-A1 | METHOD FOR TREATMENT OF XERODERMA PIGMENTOSUM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-10-04 | — | — | WO | disclosed |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-11-17 | — | — | US | disclosed |
| EP-2352729-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | Galderma Research & Development (FR) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010052256-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150329522-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC1R 1/4885MC4R 4/4885MC5R 2/4885 |
| US-20110281913-A1 | MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS | MC1R, MC5R, MC3R | MC1R 1/4885MC4R 4/4885MC5R 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.